Thus, a large amount of well-characterized and highly qualified antibodies are needed in proteomics. Purified antigen, which is not always available, has proven to be one of the rate-limiting steps in mAb large-scale generation. find more Methods: Here we describe our strategies to establish a murine hybridoma cell bank for human liver plasma using unknown native proteins as the immunogens. The antibody-recognized plasma proteins were identified by MS following immunoprecipitation (IP), and by screening of human liver cDNA expression library. Results: We found that the established antibodies
reacted specifically with a number of important Candidate cancer biomarkers, Candidate cardiovascular disease genes include FN1 in plasma and extracellular matrix. The subcellular localization of these antigens was further confirmed by immune-histocytochemistry. 48 cases Different disease liver Pathological tissue specimens were also tested for their diagnostic value by 3 strain anti-FN1 antibodies and immune-histocytochemistry AZD3965 chemical structure diagnostic value. Conclusion: We believe these well-characterized antibodies would be useful in
diagnosis and treatment of Liver disease in the near future. Key Word(s): 1. FN1; 2. monoclonal antibody; 3. Liver disease; Presenting Author: JIAN WANG Additional Authors: PENGCHANG ZHU, FENWEI XIE Corresponding Author: FENWEI XIE Affiliations: Changzheng hospital Objective: FOXA2
functions as an important regulator in endoderm-derived organs development and body homeostasis. It has been reported that FOXA2 has a great impact on EMT process through targeting E-cadherin and Snail2. Additional, FOXA2 suppression is responsible for the TNF-α induced tumorigenesis in liver. However, the role of FOXA2 in HCC metastasis is still unknown. This study aims to clarify that FOXA2 functions as a suppressor of HCC metastasis. Methods: The expression of FOXA2 was tested in HCC patients’s Carbohydrate specimens including primary tumors, adjacent tissues and portal vein tumor thrombuses. The respectively FOXA2 expression and migration ability in different human hepatoma cell lines were also detected. The effects of overexpression and knockdown of FOXA2 were investigated in FOCUS and Hep-G2, respectively. We also evaluated the expression of FOXA2 in liver cancer tissue samples from 80 patients and analyzed the relationship between FOXA2 expression and clinicopathological features. Results: We demonstrated that expression of FOXA2 was down-regulated in the process of HCC development.